<List><item><source>MED</source><extId>25918657</extId><pmcid>PMC4396905</pmcid><annotations><annotation><prefix>Phase II trial (</prefix><exact>NCT02272686</exact><postfix>) of Bruton's tyrosine k</postfix><tags><tag><name>NCT02272686</name><uri>http://identifiers.org/clinicaltrials/NCT02272686</uri></tag></tags><id>http://europepmc.org/articles/PMC4396905#europepmc-d66d4bf8247f770023877912bce9a9a8</id><type>Accession Numbers</type><section>Discussion (http://purl.org/orb/Discussion)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>r phase I/II trial (</prefix><exact>NCT02213913</exact><postfix>) is also evaluating</postfix><tags><tag><name>NCT02213913</name><uri>http://identifiers.org/clinicaltrials/NCT02213913</uri></tag></tags><id>http://europepmc.org/articles/PMC4396905#europepmc-653f499f47c271970266e488e208cf6f</id><type>Accession Numbers</type><section>Discussion (http://purl.org/orb/Discussion)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation></annotations></item></List>